| TNF alpha | Anti-tumour necrosis factor alpha |
|---|---|
| BTB | Blood-Tumour-Barrier |
| BMRTC | Bone metastasising renal tumour of childhood |
| EATC | Ehrlich Ascites tumour cells |
| GCT | Granular Cell Tumour |
| tumour | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumour angiogenesis factor | <growth factor> Substance released from a tumour that promotes vascularisation of the mass of neoplastic cells. Once a tumour becomes vascularised, it will grow more rapidly and is more likely to metastasise. TAF is almost certainly more than one substance. See: angiogenin. (18 Nov 1997) |
| tumour angiogenic factor | A substance released by solid tumours which induces formation of new blood vessels to supply the tumour. (05 Mar 2000) |
| tumour antigens | Antigens that may be frequently associated with tumours or may be specifically found on tumour cells of the same origin (tumour specific), tumour antigens may also be associated with replication and transformation by certain DNA tumour viruses, including adenoviruses and papovaviruses. Synonym: neoantigens. See: T antigens. (05 Mar 2000) |
| tumour burden | <oncology> The size of the tumour or number of abnormal cells in the organ or tissue. (16 Dec 1997) |
| tumour cell | <oncology> Cell derived from a tumour in an animal. Refers to a tumour causing malignant cell and not an adventitious normal cell. Loosely, a transformed cell able to give rise to tumours. (18 Nov 1997) |
| tumour cells, cultured | Cells grown in vitro from neoplastic tissue for use in studying the proliferative and metabolic capacities of tumour cells, in predicting clinical responses to chemotherapy, in screening new antitumour agents, and in basic biological research. They include carcinoma cell lines. (12 Dec 1998) |
| tumour debulking | Surgically removing as much of the tumour as possible. (12 Dec 1998) |
| tumour embolism | Embolism by neoplastic tissue transported from a tumour site and which may grow as a metastasis. (05 Mar 2000) |
| tumour escape | The ability of tumours to evade destruction by the immune system. Theories concerning possible mechanisms by which this takes place involve both cellular and humoral immunity, and also costimulatory pathways related to CD28 antigens and CD80 antigens. (12 Dec 1998) |
| tumour initiation | <cell biology, oncology> First stage of tumour development. See: tumour progression. (18 Nov 1997) |
| tumour lysis syndrome | <haematology, oncology, syndrome> A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterised by combinations of hyperuricaemia, lactic acidosis, hyperkalaemia, hyperphosphatemia and hypocalcaemia. (12 Dec 1998) |
| tumour marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumour necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| tumour necrosis factor-beta | <cytokine> A cytolytic factor that is produced by CD4 and CD8 T-cells after their exposure to an antigen. (05 Mar 2000) |
| acinar cell tumour | A solid and cystic tumour of the pancreas, occurring in young women; tumour cells contain zymogen granules. (05 Mar 2000) |
|---|---|
| acute splenic tumour | Acute splenitis, enlargement, and softening of the spleen, usually due to bacteraemia or severe bacterial toxaemia. (05 Mar 2000) |
| adenoid tumour | Adenoma, or neoplasm with glandlike spaces. (05 Mar 2000) |
| adenomatoid odontogenic tumour | A benign epithelial odontogenic tumour appearing radiographically as a well-circumscribed radiolucent-radiopaque lesion usually surrounding the crown of an impacted tooth in an adolescent or young adult; characterised histologically by columnar cells organised in a duct-like configuration interspersed with spindle-shaped cells and amyloid-like deposition that gradually undergoes dystrophic calcification. Synonym: adenoameloblastoma, ameloblastic adenomatoid tumour. (05 Mar 2000) |
| adenomatoid tumour | A small, circumscribed, benign tumour of the genital tract, composed of small glandlike spaces lined by flattened or cuboidal mesothelium-like cells. (12 Dec 1998) |
| adipose tumour | <oncology, tumour> Clumps of fat cells. Literally, fat cancer. These are benign tumours that can form in the breast. (16 Dec 1997) |
| adrenal gland tumour | <oncology> A benign tumour or adenoma, that usually results in the excess production of adrenal gland hormones. (27 Sep 1997) |
| adrenal rest tumour | A rare, usually benign, ovarian tumour thought to be derived from embryonic rest cells of the adrenals. This tumour causes various degrees of masculinization. (12 Dec 1998) |
| ameloblastic adenomatoid tumour | A benign epithelial odontogenic tumour appearing radiographically as a well-circumscribed radiolucent-radiopaque lesion usually surrounding the crown of an impacted tooth in an adolescent or young adult; characterised histologically by columnar cells organised in a duct-like configuration interspersed with spindle-shaped cells and amyloid-like deposition that gradually undergoes dystrophic calcification. Synonym: adenoameloblastoma, ameloblastic adenomatoid tumour. (05 Mar 2000) |
| amyloid tumour | A localised form of amyloidosis in which amyloid occurs as masses or nodules beneath the skin or mucous membranes, e.g., in the larynx. Synonym: amyloid tumour, focal amyloidosis. (05 Mar 2000) |
| angiomatoid tumour | A small, circumscribed, benign tumour of the genital tract, composed of small glandlike spaces lined by flattened or cuboidal mesothelium-like cells. (12 Dec 1998) |
| antigens, tumour-associated, carbohydrate | Carbohydrate antigens expressed by malignant tissue. They are useful as tumour markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. (12 Dec 1998) |
| antigens, viral, tumour | Those proteins recognised by antibodies from serum of animals bearing tumours induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation. (12 Dec 1998) |
| aortic body tumour | Aortic body, carotid body, chemoreceptor, or glomus jugulare tumour; nonchromaffin paraganglioma; receptoma; a relatively rare, usually benign neoplasm originating in the chemoreceptor tissue of the carotid body, glomus jugulare, and aortic bodies; consisting histologically of rounded or ovoid hyperchromatic cells that tend to be grouped in an alveolus-like pattern within a scant to moderate amount of fibrous stroma and a few large thin-walled vascular channels. Compare: paraganglioma. Synonym: aortic body tumour, carotid body tumour, chemoreceptor tumour, glomus jugulare tumour, nonchromaffin paraganglioma. Origin: chemo-+ G. Dektes, receiver, fr. Dechomai, to receive, + -oma, tumour (05 Mar 2000) |
| ascites tumour | <oncology> Tumour that grows in the peritoneal cavity as a suspension of cells. Obviously such cells have lost anchorage dependence and they can easily be isolated and passaged. Hybridomas are sometimes grown as ascites tumours and the ascites fluid can then be used as the crude antiserum. (18 Nov 1997) |
| tumour | an abnormal new mass of tissue that serves no purpose |
|---|---|
| tumour | a proinflammatory cytokine that is produced by white blood cells (monocytes and macrophages) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|